NSE: LAURUSLABS · 27 October 2026
- Laurus Labs Limited shares advanced 3.86% today, touching an intraday high of ₹2,139.10 before trading near ₹2,138.30 by the afternoon session.
- Laurus Labs invested INR 1,078,000,000 to acquire 107,800,000 equity shares of face value INR 10 each in KRKA Pharma Private Limited through a rights issue. Following this capital infusion, the company's total shareholding remains at 49%, maintaining its joint venture stake.
- Trading volume was 1.85 times the 20-day average daily volume.
Why is Laurus Labs share price rising on 27 October 2026?
Laurus Labs Limited shares advanced 3.86% today, touching an intraday high of ₹2,139.10 before trading near ₹2,138.30 by the afternoon session.
The broader market remained relatively muted, with the Nifty benchmark slipping 0.02%, while sector performance was led by the Nifty Pharma index, which gained 2.06%. Against this backdrop, Laurus Labs outperformed both the broader market and its sectoral gauge, building on a positive short-term trajectory that includes a 3.35% return over the past 5 trading days.
While no new operational catalyst was officially announced today, recent corporate updates highlight ongoing strategic positioning, including an equity investment of INR 1,078,000,000 in joint venture KRKA Pharma Private Limited and an assignment of a CareEdge-ESG 1+ rating. These developments provide broader context on the company's long-term capital allocation and sustainability profile, though today's price action appears primarily driven by strong momentum and sector-wide buying interest in pharmaceutical equities.
27.32 lakh shares traded by 27 October 2026 · 02:55 PM IST. This compares with a 20-day average daily volume of 14.77 lakh shares (1.85 times). The five-day average daily volume was 15.40 lakh shares. Separately, the NSE report for 26 October 2026 showed 8.39 lakh shares delivered, representing 45.13% of that day’s traded volume. The same report recorded 71,690 trades.
The stock moved higher alongside strong sector performance in the Nifty Pharma index, supported by elevated trading volumes that exceeded 1.85 times the 20-day average. In the absence of a same-day earnings or operational announcement, the move reflects sustained technical strength near 52-week highs.
Latest Company Developments
Laurus Labs invested INR 1,078,000,000 to acquire 107,800,000 equity shares of face value INR 10 each in KRKA Pharma Private Limited through a rights issue. Following this capital infusion, the company's total shareholding remains at 49%, maintaining its joint venture stake.
Demonstrates continued capital commitment toward expanding its joint venture footprint in key pharmaceutical markets.
CARE ESG Ratings Limited assigned an ESG rating score of 82.6, resulting in a CareEdge-ESG 1+ rating for Laurus Labs. The rating indicates a leadership position in managing environmental, social, and governance risks through structured disclosures and policies.
Enhances the company's profile among sustainability-focused institutional investors and highlights strong governance standards.
Laurus Labs Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 8.26% on 30 September 2026. This compares with 10.15% on 30 June 2026, a change of -1.89 percentage points.
The filing reported 38 MF/UTI holders.
Historical Bulk / Block Deals
What to Watch Next
- Upcoming un-audited financial results and interim dividend consideration scheduled for October 29, 2026
- Execution progress on growth capital expenditures across API, fermentation, and CDMO portfolios
- Delivery volume trends and sustenance above the 20-day average volume baseline
- Broader momentum in the Nifty Pharma sector index
Other Dated Coverage
- Laurus Labs Share Price Today: Why LAURUSLABS Is Falling 1.94% | 23 October 2026 — 23 October 2026
- Laurus Labs in Focus After Receiving CareEdge-ESG 1+ Leadership Rating | 16 October 2026 — 16 October 2026
- Laurus Labs in Focus Today After Receiving CareEdge-ESG 1+ Rating | 15 October 2026 — 15 October 2026
More Laurus Labs news and dated analysis →
Frequently Asked Questions
What is the latest Laurus Labs company news?
Laurus Labs invested INR 1,078,000,000 to acquire 107,800,000 equity shares of face value INR 10 each in KRKA Pharma Private Limited through a rights issue. Following this capital infusion, the company's total shareholding remains at 49%, maintaining its joint venture stake.
How strong was Laurus Labs’s trading volume?
27.32 lakh shares traded, 1.85 times the 20-day average daily volume. The price and volume data are dated 27 October 2026 · 02:55 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.